EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Impact of Food and Beverage on Enlicitide Pharmacokinetics and LDL ‐C Lowering

Douglas G Johns, Maja Skataric, Susan Zhou, Ferdous Gheyas, Ednan Bajwa, Puja Banka, Filippos Kesisoglou, Allen Hunt, David Bruce, Corey Anderson, Helen Manthos, Jonathan Pollock und 11 weitere

Clinical Pharmacology & Therapeutics · 06.11.2026

DOI: 10.1002/cpt.70541 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 06.11.2026. Verfasst von Douglas G Johns und 22 weiteren Autor:innen. Beteiligte Einrichtung: Translational Medicine, Merck & Co., Inc., Rahway, New Jersey, USA. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Enlicitide decanoate is a macrocyclic peptide first‐in‐class oral PCSK9 inhibitor that lowers LDL‐C, with maximal efficacy achieved when administered on an empty stomach. This work characterizes the effects of food, pre‐dose fasting duration (2–8 hours), water volume, common beverages (black coffee and plain tea), and other real‐world scenarios on enlicitide exposure and predicts the impact on clinical efficacy. Three phase I, open‐label, crossover studies in healthy participants evaluated the effects of these conditions on enlicitide exposure following a single 20 mg dose. Enlicitide steady‐state exposure and corresponding LDL‐C reductions under various conditions were predicted using population pharmacokinetic and exposure–response models. Administration of enlicitide 30 minutes after a high‐fat meal resulted in an approximately 48% reduction in steady‐state AUC and delayed absorption compared with fasted conditions (median Tmax ~8 hours vs. 0.5‐1 hour). Increasing pre‐dose fasting duration from 2 to 8 hours increased exposure. Water volume, black coffee or plain tea had no meaningful effect on enlicitide exposure. Model‐predicted LDL‐C reductions remained robust across various conditions, with LDL‐C reductions of approximately 64% under fasted conditions, 62% to 63% when occasionally administered with food or if a dose is occasionally missed, 60% with black coffee or plain tea, and 59% following a 4‐hour fast. These data support the recommended dosing and administration instructions for enlicitide, which are expected to provide ~60% LDL‐C reduction, as seen in the enlicitide phase III clinical trials. Furthermore, these findings highlight the pharmacokinetic forgiveness potential of enlicitide, suggesting that occasional departures from the recommended dosing or sporadic lapses in compliance may be tolerated with minimal impact on efficacy.

Autor:innen und Institutionen

  • Translational Medicine, Merck & Co., Inc., Rahway, New Jersey, USA.
  • Quantitative Pharmacology and Pharmacometrics, Merck & Co., Inc., Rahway, New Jersey, USA.
  • Global Clinical Development, Merck & Co., Inc., Rahway, New Jersey, USA.
  • Pharmaceutical Sciences and Clinical Supply, Merck & Co., Inc., Rahway, New Jersey, USA.
  • Celerion, Inc., Lincoln, Nebraska, USA.
  • Biostatistics, Merck & Co., Inc., Rahway, New Jersey, USA.

ORCID-Profile: Maxwell Pistilli, Islam R Younis

Zitieren

APA

Johns, D. G., Skataric, M., Zhou, S., Gheyas, F., Bajwa, E., Banka, P., Kesisoglou, F., Hunt, A., Bruce, D., Anderson, C., Manthos, H., Pollock, J., Donabella, P. J., Thompson, C., Freire, D., Giang, K., Pietrantonio, F., Wolford, D., Basak, P., …, & Younis, I. R. (2026). Impact of Food and Beverage on Enlicitide Pharmacokinetics and LDL ‐C Lowering. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70541

Vancouver

Johns DG, Skataric M, Zhou S, Gheyas F, Bajwa E, Banka P, et al. Impact of Food and Beverage on Enlicitide Pharmacokinetics and LDL ‐C Lowering. Clinical Pharmacology & Therapeutics. 2026. doi:10.1002/cpt.70541

BibTeX
@article{Johns2026,
  author = {Johns, Douglas G and Skataric, Maja and Zhou, Susan and Gheyas, Ferdous and Bajwa, Ednan and Banka, Puja and Kesisoglou, Filippos and Hunt, Allen and Bruce, David and Anderson, Corey and Manthos, Helen and Pollock, Jonathan and Donabella, Paul J and Thompson, Campbell and Freire, Daniel and Giang, Kiet and Pietrantonio, Frank and Wolford, Dennis and Basak, Piyali and Pistilli, Maxwell and Kantesaria, Bhavna and Kothare, Prajakti and Younis, Islam R},
  title = {Impact of Food and Beverage on Enlicitide Pharmacokinetics and LDL ‐C Lowering},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2026},
  doi = {10.1002/cpt.70541}
}
Kostenlos starten →